var data={"title":"Nitric oxide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitric oxide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6660?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitric-oxide-drug-information\" class=\"drug drug_general\">see &quot;Nitric oxide: Drug information&quot;</a> and <a href=\"topic.htm?path=nitric-oxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitric oxide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201946\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>INOmax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201947\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>INOmax;</li>\n      <li>Noxivent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1027922\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vasodilator, Pulmonary</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46131841\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypoxic respiratory failure associated with pulmonary hypertension:</b> Neonates &gt;34 weeks gestational age: Inhalation: 20 parts per million (ppm); maintain treatment up to 14 days or until resolution of oxygen desaturation; doses &gt;20 ppm are not recommended due to risk of methemoglobinemia and pulmonary injury from elevated nitrogen dioxide (NO<sub>2</sub>). Abrupt discontinuation may lead to worsening oxygenation and rebound pulmonary hypertension; to avoid rebound wean nitric oxide. To wean nitric oxide, titrate down in several steps (pause several hours at each step); monitor for hypoxemia. Various weaning methods have been used in clinical trials and no standard wean exists; some have suggested weaning by 5 to 10 ppm every 4 hours until the patient is stable at 5 ppm; once stable at 5 ppm, the dose should be decreased by 1 ppm every 4 hours and discontinued at 1 ppm if the patient remains well oxygenated. If deterioration occurs during weaning or after discontinuation, increase nitric oxide to the previous dose or restart; once improved, wean more slowly (Peliowski 2012; Ware 2015). <b>Note:</b> Use in preterm neonates is not recommended; nitric oxide therapy does not improve survival in preterm neonates (&lt;34 weeks) with respiratory failure and evidence does not support using in these patients to prevent BPD, severe IVH, or other neonatal morbidities (AAP [Kumar 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201929\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gas, for inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 100 ppm (1963 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 1918 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 100 ppm (353 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 344 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 800 ppm (1963 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 1918 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 800 ppm (353 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 344 L]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201914\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1027951\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administration of nitric oxide should be done by a health care professional who has completed a comprehensive periodic training program. May only be administered using a calibrated INOmax DS<sub>IR</sub> nitric oxide delivery system; only validated delivery systems should be used with nitric oxide. To prevent treatment interruptions due to power and/or system failures, immediate access to a backup battery power supply and an independent reserve nitric oxide delivery system is essential. Do not abruptly discontinue; must wean. To wean nitric oxide, titrate down in several steps, pausing several hours before reducing further; monitor for hypoxemia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201943\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store cylinders at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Adhere to all regulations related to storing pressurized vessels. Protect cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The exposure limit set by the Occupational Safety and Health Administration for nitric oxide is 25 ppm, and for NO<sub>2</sub> the limit is 5 ppm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1027923\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension used in conjunction with ventilator support and other agents to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (FDA approved for term and near-term [&gt;34 weeks gestational age] neonates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201962\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hypoxemia, methemoglobinemia, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Occupational exposure (eg, hospital staff) may result in chest discomfort, dizziness, dry throat, dyspnea, and headache.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201934\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Neonates dependent on right-to-left shunting of blood</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201918\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;Airway injury: May result from inflammation and lung tissue damage caused by nitrogen dioxide (NO<sub>2</sub>) formed in nitric oxide and oxygen gas mixtures. If there is an unexpected change in NO<sub>2</sub> concentration, or if NO<sub>2</sub> concentration in the breathing circuit reaches 3 ppm, assess delivery system and recalibrate the NO<sub>2</sub> analyzer; adjust dose of nitric oxide and/or FiO<sub>2</sub> as appropriate. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Dose-related methemoglobin (when nitric oxide combines with hemoglobin) may occur and lead to hypoxemia; monitor methemoglobin concentrations within 4 to 8 hours of starting nitric oxide treatment and then periodically; optimize oxygenation by adjusting nitric oxide dose as necessary. If methemoglobin levels do not resolve with decrease in dose or discontinuation of nitric oxide, additional therapy may be warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Use in patients with left ventricular dysfunction may increase pulmonary capillary wedge pressure, worsen left ventricular dysfunction, and cause pulmonary edema, systemic hypotension, bradycardia, and cardiac arrest; discontinue nitric oxide and provide symptomatic care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary artery hypertension (PAH) : Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred resulting in acute pulmonary edema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt discontinuation: Avoid abrupt discontinuation; may lead to worsening oxygenation, and increasing pulmonary artery pressure (PAP) (ie, rebound pulmonary hypertension syndrome). Signs and symptoms of rebound pulmonary hypertension syndrome include hypoxemia, systemic hypotension, bradycardia, and reduced cardiac output; reinitiate nitric oxide immediately if this occurs. In order to wean, titrate down in many steps (pause several hours at each step) and monitor for hypoxemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Doses above 20 ppm should not be used (or should be used with caution [off-label dosing]) because of the increased risk of methemoglobinemia and elevated levels of nitrogen dioxide (NO<sub>2</sub>), a toxic metabolite. Methemoglobin concentrations and inspired NO<sub>2</sub> should be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lack of response: Worsening oxygenation and increasing PAP may occur in patients who do not respond.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46131839\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Elevations in methemoglobin and nitrogen dioxide may be signs of overdose. Elevated nitrogen dioxide may cause acute lung injury and elevations of methemoglobin reduce the oxygen delivery capacity of the circulation. NO<sub>2</sub> levels &gt;3 ppm or methemoglobin levels &gt;7% were treated by reducing the dose of or discontinuing INOmax. Methemoglobinemia that does not resolve with dosage reduction or discontinuation of therapy may require intravenous vitamin C, intravenous methylene blue, or blood transfusion, depending on the clinical situation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use in premature neonates (GA &le;34 weeks) is not recommended based on data from trials and meta-analysis. Nitric oxide (rescue and routine use for respiratory failure) did not improve survival nor was it found effective in the prevention or amelioration of bronchopulmonary dysplasia (AAP [Kumar 2014]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299766\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201923\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106992&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: Nitric Oxide may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201925\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201937\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Nitric oxide is not indicated for use in adults. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1027954\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory status including arterial blood gases with close attention to PaO<sub>2</sub>, methemoglobin (measured within 4 to 8 hours after initiation and periodically throughout treatment with nitric oxide), inspired NO<sub>2</sub>, vital signs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201917\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates with persistent pulmonary hypertension, nitric oxide improves oxygenation. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which leads to vasodilation. When inhaled, pulmonary vasodilation occurs and an increase in the partial pressure of arterial oxygen results. Dilation of pulmonary vessels in well ventilated lung areas redistributes blood flow away from lung areas where ventilation/perfusion ratios are poor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Systemic after inhalation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nitric oxide combines with hemoglobin that is 60% to 100% oxygenated. Nitric oxide combines with oxyhemoglobin to produce methemoglobin and nitrate. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite respectively, which interact with oxyhemoglobin to then produce methemoglobin and nitrate. At 80 ppm the methemoglobin percent is ~5% in neonates after 8 hours of administration; methemoglobin levels &gt;7% were attained only in neonates receiving 80 ppm. Doses &gt;20 ppm are not recommended for use in neonatal patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201939\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>INOflo (JP);</li>\n      <li>INOmax (AT, AU, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LT, MT, NL, NO, PL, PT, RO, SE, SG, SK);</li>\n      <li>Neophyr (IE);</li>\n      <li>Nomixgen (NL);</li>\n      <li>Noxap (CZ, ES, FR, NL, PT);</li>\n      <li>Pulmonox (FI);</li>\n      <li>Solcogyn (QA);</li>\n      <li>VasoKINOX (BE, DK, ES, PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Fetus and Newborn, &ldquo;Use of Inhaled Nitric Oxide,&rdquo; <i>Pediatrics</i>, 2000, 106(2 Pt 1):344-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/10920164/pubmed\" target=\"_blank\" id=\"10920164\">10920164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RH, Keuser TJ, Walker MW, et al, &ldquo;Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension of the Newborn,&rdquo; <i>N Engl J Med</i>, 2000, 342(7):469-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/10675427/pubmed\" target=\"_blank\" id=\"10675427\">10675427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson D, Barefield ES, Kattwinkel J, et al, &ldquo;Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study: I-NO/PPHN Study Group.&rdquo; <i>Pediatrics</i>, 1998, 101(3 Pt 1):325-34. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/9480993/pubmed\" target=\"_blank\" id=\"9480993\">9480993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Inhaled Nitric Oxide in Full-Term and Nearly Full-term Infants With Hypoxic Respiratory Failure.&rdquo; The Neonatal Inhaled Nitric Oxide Study Group, <i>N Engl J Med</i>, 1997, 336(9):597-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/9036320/pubmed\" target=\"_blank\" id=\"9036320\">9036320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    INOmax (nitric oxide) [prescribing information]. Hazelwood, MO: INO Therapeutics; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. <i>Pediatrics</i>. 2014;133(1):164-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-pediatric-drug-information/abstract-text/24379225 /pubmed\" target=\"_blank\" id=\"24379225 \">24379225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peliowski A, Canadian Paediatric Society, Fetus and Newborn Committee. Inhaled nitric oxide use in newborns. <i>Paediatr Child Health</i>. 2012;17(2):95-100.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ware AM, Golombek SG. Weaning of inhaled nitric oxide: is there a best strategy? <i>J Pediatr Neonat Individual Med</i>. 2015;4(1):e040124. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106992 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201946\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F201947\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1027922\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F46131841\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201929\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F201914\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1027951\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F201943\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1027923\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201962\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201934\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201918\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46131839\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299766\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201923\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201925\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201937\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1027954\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201917\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F201933\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201939\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/106992|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitric-oxide-drug-information\" class=\"drug drug_general\">Nitric oxide: Drug information</a></li><li><a href=\"topic.htm?path=nitric-oxide-patient-drug-information\" class=\"drug drug_patient\">Nitric oxide: Patient drug information</a></li></ul></div></div>","javascript":null}